Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 97-103

  Dannull, J ^a   Belldegrun, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

CLONING VECTOR; CONFERENCE PAPER; GENE THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SUICIDE GENE;

ADENOVIRIDAE; CYTOKINES; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MALE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0031397572     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00809.x     Document Type: Article

References (49)

1. Steam ME, McGarvey T. Prostate cancer: therapeutics, diagnostic, and basic studies. Lab Invest 1992: 67: 540-52
2. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C. Science behind total androgen blockage: from gene to combination therapy. Clin Invest Med 1993; 16: 475-92
3. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6
4. Taplin ME, Bubley GJ, Shuster TO. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl J Med 1995; 332: 1393-8
5. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990; 2: 345-54
6. Umbas R, Isaacs WB, Bringuier PP et al Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994: 54: 3929-33
7. Dong JT, Lamb PW, Rinker-Schaeffer CW et al. KAU. a metastasis suppressor gene for prostate cancer on human chromosome 11 pi 1.2. Science 1995; 268: 884-6
8. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-7
9. Crystal RG, McEivaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51
10. Yang Y, Trinchieri G, Wilson JM et al. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Medicine 1995; 1: 890-3
11. Fang B, Eisensmith RC, Wang H et al. Gene therapy for hemophilia B. host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-44
12. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616-29
13. Navone NM, Troncosco P. Pisters LL et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-69
14. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-48
15. El-Diery WS, Harper JW, Oconner PM et al. Waf1JCip1 is induced in p53 mediated Gl arrest and apoptosis. Cancer Res 1994; 54: 1169-74
16. Thompson T, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989; 56: 917-30
17. Thompson TC, Park SH, Timme TL et al. Loss of p53 function leads to metastasis in ras + myc initiated mouse prostate cancer. Oncogene 1995; 10: 869-79
18. Yang C, Cirelli C, Capogrossi MC, Passaniti A. Adenovirus mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostate tumor cells. Cancer Res 1995; 55: 4210-13
19. Phillips SM. Barton CM, Lee SJ et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-7
20. Rubin SJ, Hallahan DE, Ashman CR et al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991; 46: 3136
21. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 1990; 247: 712-15
22. Xu HJ, Xu K, Zhou Y, Li J, Benedict WF, Hu SX. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Nat Acad Sei USA 1994; 91: 9837-41
23. Donovan JF, Lubaroff DM, Williams RD. Inununotherapy of prostate cancer. Probl Urol 1990; 4: 489-505
24. Choe BK, Frost P, Morrison MK, Rose NR. Natural killer cell activity of prostatic cancer patients. Cancer Invest 1987; 5: 285-91
25. Vieweg J, Rosenthal F, Bannerji R et cd. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine modified tumor vaccines. Cancer Res 1994; 54: 1760-5
26. Sanda MG, Ayyagari SR, Jaffe EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-8
27. Sokoloff MH, Tso CL, Kaboo R et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996; 77; 1862-72
28. Oldfleld EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson W. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-49
29. Freeman SM, Abboud CN, Abraham M et al The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83
30. Maxwell IH, Maxwell F, Glode LM. Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Res 1986; 46: 4660-4
31. Riegman PHJ, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991; 5: 1921-30
32. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44
33. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol 1993; 7: 4-11
34. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand induced homodimer. Cell 1988; 55: 145-56
35. Wonk Cl, Zhou ZX, Sar M, Wilson EM. Steroid requirement for androgen receptor dimerisation and DNA binding. J Biol Chem 1993; 268: 19004-12
36. Denison SH, Sands A, Tindall DJ. A tyrosine aminotransferase glucocorticoid response element also mediates androgen enhancement of gene expression. Endocrinology 1989; 124: 1091-3
37. Rennie PS, Bruchovsky N, Leco KJ et al. Characterisation of two cis acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993: 7: 23-36
38. Fabre S, Manin M, Pailhoux E, Veryssiere G, Jean C. Identification of a functional androgen response element in the gene for the androgen-regulated aldose reductase-like protein specific to the mouse vas deferens. J Biol Chem 1994; 269: 5857-64
39. Dube JY, Chapdelaine P, Guerin S et al. Search for androgen responsive elements in the proximal promoter of the canine prostate arginine esterase gene. J Androl 1995; 16: 304-11
40. Celis L, Claessens F, Peeters B, Heyns W, Verhoeven G, Rombauts W. Proteins interacting with an androgenresponsive unit in the, C3 (1) gene intron. Mol Cell Endocrinol 1993; 94: 165-72
41. Schule R, Muller M. Otsuka-Murakami H, Renkawitz R. Many transcription factors interact synergistically with steroid receptors. Science 1988; 242: 1418-20
42. Murtha P, Tindall DJ. Young CYF. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterisation of an androgen response element in the 5′ promoter region of the gene. Biochemistry 1993; 32: 6459-64
43. Clark AR, Docherty K. Negative regulation of transcription in eukaryotes. Biochem J 1993; 296: 521-41
44. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive and negative regulation from a single DNA element. Science 1990; 249: 1266-72
45. Kupfer SR. Marschke KB, Wilson EM. French FS. Receptor accessory factor enhances specific DNA binding of androgen and glucocorticoid receptors. J Biol Chem 1993; 268: 17519-27
46. Adler AJ, Danielsen M, Robins DA. Androgen-speciflc gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Nat Acad Sei USA 1992; 89: 11660-3
47. Pang S. Taneja S, Dardashti K et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 1995; 6: 1417-26
48. Pang S, Dannull J, Kaboo R, Xie Y, deKernion JB, Belldegrun A. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997; 57: in press
49. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996; 271: 7043-51